Fluid overload sends heart failure and cirrhosis patients back to hospital. We are building a way to see it coming.
Heart failure drives over 1.2 million U.S. hospital admissions a year, at a cost of tens of billions of dollars. Most begin with the same event: fluid overload.
We are building a wearable monitoring platform that measures fluid directly, so millions of heart and liver patients can stay healthy, and stay home.
Where we are
Roughly CAD $15,000 of founder capital bought all of this. We will reach first-in-patient data for under CAD $35,000 all-in, and will not open a pre-seed round until that data exists.
How we go to market
We sell first to the people who know the disease. A specialist practice gets patients with daily support who see and own their fluid data, a stronger clinic relationship, and recurring revenue under existing billing codes. One clinic at a time, that builds product intelligence and health-system champions before we approach a hospital or insurer.
Follow the work
We publish a one-page update each quarter and report milestones met and missed. No claims ahead of data.